These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23236415)

  • 1. Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs.
    Berger WT; Ralph BP; Kaczocha M; Sun J; Balius TE; Rizzo RC; Haj-Dahmane S; Ojima I; Deutsch DG
    PLoS One; 2012; 7(12):e50968. PubMed ID: 23236415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.
    Yan S; Elmes MW; Tong S; Hu K; Awwa M; Teng GYH; Jing Y; Freitag M; Gan Q; Clement T; Wei L; Sweeney JM; Joseph OM; Che J; Carbonetti GS; Wang L; Bogdan DM; Falcone J; Smietalo N; Zhou Y; Ralph B; Hsu HC; Li H; Rizzo RC; Deutsch DG; Kaczocha M; Ojima I
    Eur J Med Chem; 2018 Jun; 154():233-252. PubMed ID: 29803996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia.
    Kaczocha M; Rebecchi MJ; Ralph BP; Teng YH; Berger WT; Galbavy W; Elmes MW; Glaser ST; Wang L; Rizzo RC; Deutsch DG; Ojima I
    PLoS One; 2014; 9(4):e94200. PubMed ID: 24705380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Antinociceptive Agent SBFI-26 Binds to Anandamide Transporters FABP5 and FABP7 at Two Different Sites.
    Hsu HC; Tong S; Zhou Y; Elmes MW; Yan S; Kaczocha M; Deutsch DG; Rizzo RC; Ojima I; Li H
    Biochemistry; 2017 Jul; 56(27):3454-3462. PubMed ID: 28632393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty-acid-binding protein inhibition produces analgesic effects through peripheral and central mechanisms.
    Peng X; Studholme K; Kanjiya MP; Luk J; Bogdan D; Elmes MW; Carbonetti G; Tong S; Gary Teng YH; Rizzo RC; Li H; Deutsch DG; Ojima I; Rebecchi MJ; Puopolo M; Kaczocha M
    Mol Pain; 2017 Jan; 13():1744806917697007. PubMed ID: 28326944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of intracellular carriers for the endocannabinoid anandamide.
    Kaczocha M; Glaser ST; Deutsch DG
    Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6375-80. PubMed ID: 19307565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of fatty acid amide hydrolase and fatty acid binding protein 5 in the uptake of anandamide by cell lines with different levels of fatty acid amide hydrolase expression: a pharmacological study.
    Björklund E; Blomqvist A; Hedlin J; Persson E; Fowler CJ
    PLoS One; 2014; 9(7):e103479. PubMed ID: 25078278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid binding protein deletion suppresses inflammatory pain through endocannabinoid/N-acylethanolamine-dependent mechanisms.
    Kaczocha M; Glaser ST; Maher T; Clavin B; Hamilton J; O'Rourke J; Rebecchi M; Puopolo M; Owada Y; Thanos PK
    Mol Pain; 2015 Aug; 11():52. PubMed ID: 26311517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in the brain.
    Yu S; Levi L; Casadesus G; Kunos G; Noy N
    J Biol Chem; 2014 May; 289(18):12748-58. PubMed ID: 24644281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice.
    Nicolussi S; Viveros-Paredes JM; Gachet MS; Rau M; Flores-Soto ME; Blunder M; Gertsch J
    Pharmacol Res; 2014 Feb; 80():52-65. PubMed ID: 24412246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty acid-binding proteins 5 and 7 gene deletion increases sucrose consumption and diminishes forced swim immobility time.
    Hamilton J; Koumas C; Clavin BH; Marion M; Figueiredo A; Gonzalez S; O'Rourke JR; Deutsch D; Kaczocha M; Haj-Dahmane S; Thanos PK
    Behav Pharmacol; 2018 Sep; 29(6):503-508. PubMed ID: 29570114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FABP-1 gene ablation impacts brain endocannabinoid system in male mice.
    Martin GG; Chung S; Landrock D; Landrock KK; Huang H; Dangott LJ; Peng X; Kaczocha M; Seeger DR; Murphy EJ; Golovko MY; Kier AB; Schroeder F
    J Neurochem; 2016 Aug; 138(3):407-22. PubMed ID: 27167970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystallographic study of FABP5 as an intracellular endocannabinoid transporter.
    Sanson B; Wang T; Sun J; Wang L; Kaczocha M; Ojima I; Deutsch D; Li H
    Acta Crystallogr D Biol Crystallogr; 2014 Feb; 70(Pt 2):290-8. PubMed ID: 24531463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR study on Novel truxillic acid monoester-Based inhibitors of fatty acid binding proteins as Next-Generation antinociceptive agents.
    Wang H; Taouil A; Awwa M; Clement T; Zhu C; Kim J; Rendina D; Jayanetti K; Maharaj A; Wang L; Bogdan D; Pepe A; Kaczocha M; Ojima I
    Bioorg Chem; 2022 Dec; 129():106184. PubMed ID: 36244323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
    Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
    Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies.
    Shimamoto C; Ohnishi T; Maekawa M; Watanabe A; Ohba H; Arai R; Iwayama Y; Hisano Y; Toyota T; Toyoshima M; Suzuki K; Shirayama Y; Nakamura K; Mori N; Owada Y; Kobayashi T; Yoshikawa T
    Hum Mol Genet; 2014 Dec; 23(24):6495-511. PubMed ID: 25027319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling.
    Farrell M; Fairfield H; Karam M; D'Amico A; Murphy CS; Falank C; Pistofidi RS; Cao A; Marinac CR; Dragon JA; McGuinness L; Gartner CG; Iorio RD; Jachimowicz E; DeMambro V; Vary C; Reagan MR
    Elife; 2023 Mar; 12():. PubMed ID: 36880649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FABP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain.
    Bogdan DM; Studholme K; DiBua A; Gordon C; Kanjiya MP; Yu M; Puopolo M; Kaczocha M
    Sci Rep; 2022 Jun; 12(1):9241. PubMed ID: 35655086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anandamide uptake explained?
    Fowler CJ
    Trends Pharmacol Sci; 2012 Apr; 33(4):181-5. PubMed ID: 22297258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
    Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
    Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.